Propel Bio Management, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Propel Bio Management, LLC disclosed 21 US equity positions worth $100.7m in its Q4 2024 13F filing. The largest position was PAGPEUR at 23.2% of the reported book, followed by MDGL and AKERO THERAPEUTICS INC. Against the Q3 2024 filing, it opened 2 new positions, added to 4 and reduced 2 among the top 21 holdings.
What did Propel Bio Management, LLC own in Q4 2024? Top 21 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HOLDINGS LP-CL | 23.2% | $23.4m | 1,272,360 | 0% | held | |
| 2 | MDGL MADRIGAL PHARMACEUTICALS | Healthcare | 13.2% | $13.3m | 43,032 | 0% | held |
| 3 | AKERO THERAPEUTICS INC | 9.5% | $9.6m | 343,729 | 0% | held | |
| 4 | ACHV ACHIEVE LIFE SCIENCES INC | 8.6% | $8.6m | 2,453,092 | 0% | held | |
| 5 | APLT APPLIED THERAPEUTICS INC | 8.2% | $8.2m | 9,615,420 | 46% | added | |
| 6 | PHAT PHATHOM PHARMACEUTICALS I | 8.0% | $8.0m | 989,927 | 14% | added | |
| 7 | TCRX TSCAN THERAPEUTICS INC | 6.3% | $6.3m | 2,087,139 | 0% | held | |
| 8 | RNAGBP AVIDITY BIOSCIENCES INC | 5.2% | $5.2m | 178,500 | 0% | held | |
| 9 | ARDX ARDELYX INC | Healthcare | 4.8% | $4.8m | 950,947 | -11% | reduced |
| 10 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.5% | $3.5m | 624,022 | 0% | held |
| 11 | SNDX SYNDAX PHARMACEUTICALS IN | Healthcare | 2.4% | $2.4m | 183,259 | 38% | added |
| 12 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.3% | $2.3m | 56,359 | 0% | held |
| 13 | ZVRA ZEVRA THERAPEUTICS INC | 1.5% | $1.5m | 179,874 | 0% | held | |
| 14 | KURA KURA ONCOLOGY INC | Healthcare | 1.1% | $1.1m | 130,000 | 0% | held |
| 15 | ATHIRA PHARMA INC | 0.9% | $875.8k | 1,492,792 | 0% | held | |
| 16 | 72C EIGER BIOPHARMACEUTICALS | 0.8% | $765.0k | 146,381 | 0% | held | |
| 17 | JSPR JASPER THERAPEUTICS INC | 0.4% | $427.6k | 20,000 | – | new | |
| 18 | DCTH DELCATH SYSTEMS INC | 0.2% | $204.7k | 17,000 | – | new | |
| 19 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.1% | $95.3k | 25,209 | -68% | reduced |
| 20 | MAAT PHARMA SACA | 0.0% | $25.1k | 3,151 | 31% | added | |
| 21 | CHINOOK THERAPEUTICS | 0.0% | $9.8k | 79,357 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.